Core Insights - Aditxt has acquired Ignite Proteomics to enhance cancer care by optimizing therapy selection for patients with metastatic cancer and limited treatment options [1][2] - Ignite's functional proteomics platform can identify therapy responses that standard genomic testing may miss, addressing a significant challenge in precision oncology [1] Group 1: Acquisition Details - Aditxt acquired Ignite Proteomics for an aggregate value of $36 million, represented by 36,000 shares of Series A-2 Convertible Preferred Stock [2] - Ignite will function as a subsidiary within Aditxt's oncology initiatives, focusing on therapy selection and longitudinal monitoring [2] Group 2: Market Opportunity - The global cancer profiling market is estimated at approximately $14 billion, with Ignite identifying a $3 billion serviceable opportunity among patients eligible for antibody drug conjugate therapies [1] - The demand for tools that determine whether a patient's tumor expresses functional protein targets is increasing due to the expansion of targeted cancer therapies [1] Group 3: Functional Proteomics Platform - Ignite's Reverse Phase Protein Array (RPPA) platform measures protein expression and activity, providing insights that complement genomic testing [1] - The platform has shown potential in predicting therapy responses, outperforming traditional assays in clinical trials [1] Group 4: Collaborations and Validation - Ignite is collaborating with leading cancer institutions, including Dana-Farber Cancer Institute and Vanderbilt University Medical Center, to validate its platform [1] - A partnership with Inova Health aims to apply the RPPA platform to guide treatment decisions for late-stage gastrointestinal cancer patients [1]